Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Prevention and treatment of synucleinopathic and amyloidogenic disease

a technology of amyloid and amyloid, which is applied in the field of prevention and treatment of synucleinopathic and amyloidogenic disease, can solve the problems of asymptomatic patients and patients with risk factors for the disease, and achieve the effect of improving patient motor characteristics and preventing deterioration of patient motor characteristics

Active Publication Date: 2013-08-13
PROTHENA BIOSCI LTD +1
View PDF99 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The invention provides methods for preventing or treating diseases associated with the buildup of alpha-SN and Lewy bodies in the brain, which can lead to Parkinson's disease and Alzheimer's disease. The methods involve inducing an immunogenic response against alpha-SN through the administration of an immunogen or antibody. The methods can be used regardless of whether the patient is symptomatic or has a risk factor for the disease. The administration of the agent can improve motor characteristics in patients with Parkinson's disease and prevent disease progression in patients at risk for Parkinson's disease. The methods can also reduce levels of alpha-synuclein oligomers and clears synuclein through the activation of a lysosomal pathway.

Problems solved by technology

In some methods the patient has a risk factor for the disease and is asymptomatic.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Prevention and treatment of synucleinopathic and amyloidogenic disease
  • Prevention and treatment of synucleinopathic and amyloidogenic disease
  • Prevention and treatment of synucleinopathic and amyloidogenic disease

Examples

Experimental program
Comparison scheme
Effect test

example i

Immunization of Human Alpha-Synuclein Transgenic Mice with Human Alpha-Synuclein Results in the Production of High Titer Anti-Alpha-Synuclein Antibodies that Cross the Blood-Brain Barrier

[0282]Full-length recombinant human alpha-SN was resuspended at a concentration of 1 mg / ml in 1× phosphate buffered saline (PBS). For each injection, 50 μl of alpha-SN was used; giving a final concentration of 50 μg per injection to which 150 μl of 1× PBS was added. Complete Freund's adjuvant (CFA) was then added 1:1 to either alpha-SN or PBS alone (control), vortexed and sonicated to completely resuspend the emulsion. For the initial injections, eight D line human alpha-SN transgenic (tg) single transgenic 4-7 months old mice (Masliah, et al. Science 287:1265-1269 (2000) received injections of human alpha-SN in CFA and, as control, four D line human alpha-SN tg mice received injections of PBS in CFA. Mice received a total of 6 injections. Three injections were performed at two weeks intervals and t...

example ii

In Vitro Screen for Antibodies Clearing Synuclein Inclusions

[0284]GT1-7 neuronal cell (Hsue et al. Am. J. Pathol. 157:401-410 (2000)) were transfected with a pCR3.1-T expression vector (Invitrogen, Carlsbad, Calif.) expressing murine alpha-SN and compared with cells transfected with expression vector alone (FIG. 3, panels B and A respectively). Cells transfected with vector alone (panel A) have a fibroblastic appearance while cells transfected with alpha-SN are rounded, with inclusion bodies at the cell surface visible via both light and confocal scanning microscopy. Transfected cells were then treated with rabbit preimmune serum (panel C) or 67-10, an affinity purified rabbit polyclonal antibody against a murine alpha-SN C terminal residues 131-140 (Iwai, et al., Neuron 14:467 (1995) (panel D). It can be seen that the inclusion bodies stain less strongly in panel D than in panel C indicating that the antibody against alpha synuclein was effective in clearing or preventing the devel...

example iii

Prophylactic and Therapeutic Efficacy of Immunization with Alpha-Synuclein

[0286]i. Immunization of Human Alpha-synuclein tg Mice

[0287]For this study, heterozygous human alpha-SN transgenic (tg) mice (Line D) (Masliah et al., Am. J. Pathol (1996) 148:201-10) and nontransgenic (nontg) controls are used. Experimental animals are divided into 3 groups. For group I, the preventive effects of early immunization by immunizing mice for 8 months beginning at 2 months of age are tested. For group II, young adult mice are vaccinated for 8 months beginning at the age of 6 months to determine whether immunization can reduce disease progression once moderate pathology had been established. For group III, older mice are immunized for 4 months beginning at the age of 12 months to determine whether immunization can reduce the severity of symptoms once robust pathology has been established. For all groups, mice are immunized with either recombinant human alpha-SN plus CFA or CFA alone, and for each e...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.

Description

NAMES OF PARTIES TO JOINT RESEARCH AGREEMENT[0001]The claimed invention was made pursuant to a joint written research agreement between Elan Pharmaceuticals, Inc. and The Regents of the University of California.BACKGROUND OF THE INVENTION[0002]Alpha-synuclein (alphaSN) brain pathology is a conspicuous feature of several neurodegenerative diseases, including Parkinson's disease (PD), dementia with Lewy bodies (DLB), the Lewy body variant of Alzheimer's disease (LBVAD), multiple systems atrophy (MSA), and neurodegeneration with brain iron accumulation type-1 (NBIA-1). Common to all of these diseases, termed synucleinopathies, are proteinaceous insoluble inclusions in the neurons and the glia which are composed primarily of alphaSN.[0003]Lewy bodies and Lewy neurites are intraneuronal inclusions which are composed primarily of alphaSN. Lewy bodies and Lewy neurites are the neuropathological hallmarks Parkinson's disease (PD). PD and other synucleinopathic diseases have been collectivel...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(United States)
IPC IPC(8): A61K39/395
CPCA61K38/1709A61K39/00C07K16/18A61K2039/505A61P25/16A61P25/28A61K38/17A61K39/395
Inventor SCHENK, DALE B.MASLIAH, ELIEZERBUTTINI, MANUELCHILCOTE, TAMIE J.ROCKENSTEIN, EDWARD M.GAMES, KATE DORA
Owner PROTHENA BIOSCI LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com